InvestSMART

Percheron Therapeutics Limited (ASX:PER)

ALERT: Price-sensitive ASX Announcement for PER
Current share price for PER : $0.004 -0.007 (-65%)+
Announcement
Release
26 Jun 2025 10:18AM
Price at Release
$0.010
Full Release
download
Summary
Percheron Therapeutics Limited (PER), a newly incorporated clinical-stage biotechnology company, announced that it has entered into an exclusive license agreement with Hummingbird Bioscience to develop and commercialize HMBD-002, a novel anti-VISTA IgG4 antibody, for all therapeutic applications worldwide except Greater China. The agreement grants Percheron exclusive worldwide rights (excluding Greater China) to research, develop, manufacture, and commercialize HMBD-002. HMBD-002 is a clinical-stage, first-in-class VISTA antagonist antibody with potential applications in immuno-oncology. The agreement underscores Percheron's commitment to advancing innovative therapies and expanding its oncology pipeline with first-in-class programs. The transaction includes upfront and milestone payments as well as royalties on net sales, and Percheron aims to accelerate the development of HMBD-002 in oncology indications.
Key Points
  • Percheron Therapeutics Limited (PER) announced an exclusive global license agreement with Hummingbird Bioscience.
  • Percheron receives rights to develop, manufacture, and commercialize HMBD-002 outside Greater China.
  • HMBD-002 is a clinical-stage, first-in-class anti-VISTA IgG4 antibody targeting immuno-oncology indications.
  • The license includes upfront, milestone, and royalty payments to Hummingbird Bioscience.
  • Percheron is committed to advancing HMBD-002 in oncology with the goal of accelerating clinical development.
  • The agreement supports Percheron's strategy of building an innovative oncology pipeline.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.